Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WELLCOVORIN vs AKTOB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Folinic acid (leucovorin) is a reduced form of folic acid that bypasses dihydrofolate reductase inhibition, providing cofactors for nucleotide synthesis and reversing the effects of folate antagonists such as methotrexate.
Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.
Rescue therapy after high-dose methotrexate therapy in osteosarcoma,Treatment of advanced colorectal cancer in combination with fluorouracil (off-label),To diminish toxicity and counteract effects of folic acid antagonists (e.g., trimethoprim, pyrimethamine) in certain infections
Prevention of organ rejection in kidney, liver, and heart transplants,Rheumatoid arthritis,Psoriasis
WELLCOVORIN (levoleucovorin) is administered intravenously or intramuscularly at a dose of 7.5 mg (approximately 0.1 mg/kg) every 6 hours for 10 doses starting 24 hours after the end of methotrexate infusion. Alternatively, 15 mg orally every 6 hours for 10 doses, starting 24 hours after methotrexate infusion.
Adults: 10 mg orally once daily.
The terminal elimination half-life of folinic acid (active reduced folate) is approximately 6-7 hours in patients with normal renal function. The pharmacologically active metabolite, 5-methyltetrahydrofolate, has a longer half-life of about 10-12 hours. In renal impairment, half-life may be prolonged.
Terminal elimination half-life is 8-12 hours; prolonged in renal impairment (up to 20-30 hours in anuria).
Folinic acid is metabolized via reduction and methylation to active folate forms (e.g., 5-methyltetrahydrofolate) in the liver and other tissues. Involves dihydrofolate reductase and other folate-metabolizing enzymes.
Hepatic via CYP3A4 enzyme system; major metabolites include AM1, AM9, and AM4N.
Primarily renal excretion as unchanged drug and metabolites; about 80-90% of a dose is excreted in urine within 24 hours, with approximately 50-70% as unchanged folinic acid and the remainder as 5-methyltetrahydrofolate and other metabolites. Fecal excretion accounts for <10%.
Renal: 70-80% unchanged; biliary/fecal: 10-15% as metabolites.
Approximately 15% bound to plasma proteins, mainly albumin. Binding is not extensive.
20-30% primarily to albumin.
Volume of distribution is approximately 0.5-0.6 L/kg, indicating distribution into total body water and some tissue binding. It crosses the blood-brain barrier poorly.
0.25-0.4 L/kg; indicates distribution primarily in extracellular fluid.
Oral bioavailability is variable: approximately 25-30% for the active isomer (l-folinic acid) due to first-pass metabolism; the racemic mixture (d,l-folinic acid) has a lower absolute bioavailability of about 30% for the active component. Intravenous and intramuscular routes provide 100% bioavailability.
Intramuscular: approximately 90%; oral: not absorbed (0% due to degradation in GI tract).
No specific GFR-based dose modifications are provided in the prescribing information. However, levoleucovorin is renally eliminated, and caution is advised in patients with renal impairment. For severe renal impairment (Cr Cl < 10 m L/min), consider dose reduction or extended interval. Monitor methotrexate levels and adjust leucovorin dose accordingly.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min or dialysis: 2.5 mg once daily.
No specific dose adjustments are recommended for hepatic impairment based on Child-Pugh class. However, caution is advised in patients with significant hepatic dysfunction due to potential altered folate metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
WELLCOVORIN is not FDA approved for pediatric use. However, in pediatric patients, levoleucovorin is sometimes used at a dose of 10 mg/m² (or 0.2 mg/kg) every 6 hours for 5-7 doses, starting 24 hours after methotrexate infusion, adjusted based on methotrexate levels. Dosing should be individualized based on clinical response and methotrexate concentration.
Not established for children <18 years.
No specific geriatric dose adjustments are recommended. Due to age-related decline in renal function, monitor renal function and methotrexate levels closely, and consider dose adjustment based on creatinine clearance.
No specific dose adjustment; monitor for hypotension and renal function.
No FDA black box warning.
Increased risk of lymphomas and other malignancies, particularly of the skin. Increased susceptibility to infections. Cyclosporine can cause nephrotoxicity and hepatotoxicity.
May mask pernicious anemia and other megaloblastic anemias due to vitamin B12 deficiency; caution in patients with renal impairment; hypersensitivity reactions; gastrointestinal toxicity with 5-FU combination.
Nephrotoxicity, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, increased risk of infections and malignancies, anaphylaxis (IV formulation).
History of severe hypersensitivity to folinic acid; pernicious anemia or other megaloblastic anemias secondary to vitamin B12 deficiency.
Hypersensitivity to cyclosporine or any component of the formulation, abnormal renal function, uncontrolled hypertension, malignancies, concurrent use with PUVA or UVB therapy in psoriasis.
No significant food interactions have been reported. However, maintain adequate hydration and avoid alcohol due to potential hepatotoxicity. No specific dietary restrictions are required.
No significant food interactions. Avoid alcohol while taking this medication.
WELLCOVORIN (levoleucovorin) is a folate analog. Folate is essential for fetal development. Wellcovorin is the active enantiomer of leucovorin, which is used to counteract folic acid antagonists. Available data do not indicate an increased risk of major birth defects with therapeutic doses. However, high-dose methotrexate therapy (which Wellcovorin is used to rescue from) is teratogenic. During first trimester, folate supplementation is protective against neural tube defects. During second and third trimester, folate requirements increase. No specific fetal risks are known from Wellcovorin alone. However, the underlying condition requiring treatment may pose risks.
First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; monitor for fetal growth restriction and oligohydramnios.
Levoleucovorin is excreted into human milk. The M/P ratio is not established. Due to low molecular weight, excretion is expected. Exposure to the breastfed infant is likely low. Caution is advised. Use only if clearly needed.
Not recommended during breastfeeding. M/P ratio unknown; potential infant exposure via milk.
Pregnancy increases folate clearance. Dose may need adjustment to maintain adequate serum folate levels, especially in high-dose methotrexate rescue. Monitor serum folate and adjust dose accordingly. Specific dose changes are not established; clinical judgment and monitoring are required.
No standard dose adjustment; increased clearance in pregnancy may require higher doses; therapeutic drug monitoring advised.
WELLCOVORIN (levoleucovorin) is the active l-isomer of leucovorin; it does not require metabolic activation and is preferred in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. It is used to reduce the toxicity of methotrexate (MTX) and to enhance the efficacy of fluorouracil (5-FU). When used for MTX rescue, initiate 24 hours after start of MTX infusion; monitor serum MTX levels, creatinine, and urine p H. Rescue dose and duration depend on MTX levels; continue until MTX level < 0.05 μmol/L. For 5-FU modulation, administer immediately before or simultaneously with 5-FU; do not use with irinotecan due to increased diarrhea risk.
AKTOB is a beta-lactam antibiotic; monitor for hypersensitivity reactions, especially in patients with penicillin allergy. Adjust dose in renal impairment (Cr Cl <30 m L/min). Administer by slow IV infusion over 3-5 minutes or as directed. Observe for signs of Clostridioides difficile infection.
Take this medication exactly as prescribed; do not change the dose or frequency without consulting your doctor.,This drug may be given as an injection or as an oral tablet; follow the instructions for the specific formulation you receive.,If you miss a dose, contact your healthcare provider; do not double the next dose.,Report any signs of allergic reaction (rash, hives, swelling, difficulty breathing) or severe gastrointestinal symptoms (severe diarrhea, vomiting, abdominal pain) immediately.,Drink plenty of fluids to stay hydrated, especially during chemotherapy treatment.,Avoid alcohol while taking this medication as it may increase the risk of liver toxicity.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Complete the full course of therapy even if symptoms improve.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,Inform your doctor if you have kidney problems or are on dialysis.,This medication may cause diarrhea; do not treat with anti-diarrheal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Common clinical questions about WELLCOVORIN vs AKTOB, answered by our medical review team.
WELLCOVORIN is a Folic Acid Derivative that works by Folinic acid (leucovorin) is a reduced form of folic acid that bypasses dihydrofolate reductase inhibition, providing cofactors for nucleotide synthesis and reversing the effects of folate antagonists such as methotrexate.. AKTOB is a Aminoglycoside Antibiotic (Ophthalmic) that works by Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WELLCOVORIN and AKTOB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WELLCOVORIN is: WELLCOVORIN (levoleucovorin) is administered intravenously or intramuscularly at a dose of 7.5 mg (approximately 0.1 mg/kg) every 6 hours for 10 doses starting 24 hours after the end of methotrexate infusion. Alternatively, 15 mg orally every 6 hours for 10 doses, starting 24 hours after methotrexate infusion.. The standard adult dose of AKTOB is: Adults: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WELLCOVORIN and AKTOB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WELLCOVORIN is classified as Category C. WELLCOVORIN (levoleucovorin) is a folate analog. Folate is essential for fetal development. Wellcovorin is the active enantiomer of leucovorin, which is used to counteract folic ac. AKTOB is classified as Category C. First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.